A study comparing krill oil with fish oil has found that krill may effectively influence the human endocannabinoid system in obese persons, which could influence physiological processes like mood and appetite.
A study comparing krill oil with fish oil has found that krill may effectively influence the human endocannabinoid (EC) system in obese persons, which could influence physiological processes like mood and appetite.
Normal, overweight, and obese subjects given 2 grams of krill oil, menhaden fish oil, or olive oil daily for four weeks, and EC plasma levels were measured.
Krill oil ingredient supplier Aker Biomarine (Oslo, Norway) announced the results earlier this week, noting that increases in ECs were linked to a “relatively low dose” of 309 mg of the omega-3s EPA (eicosapentaenoic acid)/DHA (docosahexaenoic acid).
Previous research indicates that obese persons have elevated blood levels of the “fat-signaling markers,” according to Aker Biomarine.
“This is an important finding confirming previous outcomes with krill oil in obese animals,” said Nils Hoem, PhD, a chief scientist at the company. “Helping normalize endocannabanoid levels in obese subjects may help address potential long-term health issues, including metabolic syndrome, though these are preliminary findings and additional research is necessary to draw solid conclusions.”
Results of this study on krill oil and fat-signaling markers is available have been published in the journal Nutrition & Metabolism.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.